Are you a healthcare professional seeking innovative treatment options for your patients with metastatic KRAS G12C non-small cell lung cancer (NSCLC)? If so, the SHERLOCK clinical trial may be the answer. This study, led by TOGA and coordinated by the NHMRC CTC, is investigating a new treatment combination.
A Promising New Treatment
The SHERLOCK trial is exploring the effectiveness of Sotorasib, an oral medication, in combination with Carboplatin, Pemetrexed, and Bevacizumab. The primary goal of the study is to assess the objective tumour response rate, as measured by Recist 1.1. Additionally, the trial will evaluate key secondary endpoints such as progression-free survival, overall survival, duration and depth of response, and adverse events.
Why Participate in SHERLOCK?
- Early Access to Innovative Therapy: SHERLOCK offers your patients early access to Sotorasib in the first-line setting for KRAS G12C NSCLC, at no cost.
- Building on Promising Results: Data from other studies, such as SCARLET and CodeBreaK 100, have demonstrated the potential benefits of Sotorasib.
- Contributing to Medical Advancement: By participating in SHERLOCK, you’ll help advance the understanding of KRAS G12C NSCLC and contribute to the development of future treatment options.
As Study Chair, A/Prof Surein Arulananda explains:
“Innovative and adventurous like the famous Baker Street detective himself, the SHERLOCK study provides access to a novel targeted therapy for patients with first line KRAS G12C mutant lung cancer in combination with chemotherapy and bevacizumab biosimilar. This is an innovative strategy and mimics the experience we have seen in almost all aspects of oncogene-driven lung cancers, whereby early use of targeted therapies improve patient outcomes and quality of life. This uniquely Australian study will provide critical data for future study designs so that we can bring early targeted therapy to all patients with KRASG12C mutant lung cancers in the not so distant future.” – A/Prof Surein Arulananda, Study Chair
Join the SHERLOCK Mission
If you have patients who may be eligible for the SHERLOCK trial, please consider referring them. Together, we can make a difference in the lives of patients with KRAS G12C NSCLC.
The trial is on the final stretch of the study, with recruitment at 43 out of 52 participants. Recruitment will hopefully be finalised by early 2025.
For more information, please contact sherlock.study@sydney.edu.au
